ArticleJTCVS structural and endovascular2026
Hospital volume and efficiency in transcarotid transcatheter aortic valve replacement: Insights from a national database of 10,000+ cases.
Article in JTCVS structural and endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: When transfemoral transcatheter aortic valve replacement (TAVR) is unsuitable, transcarotid TAVR offers a safe alternative. The relationship between hospital procedural volume and clinical outcomes remains unclear, and solidifying this relationship is key to establishing benchmarks and guiding high-quality care. Methods: We retrospectively analyzed US academic centers in the Vizient Clinical Database, a national repository of tertiary and quaternary hospital data. All centers performing transcarotid TAVR in 2022 to 2024 were included. Patient demographics and outcomes were compared using the Kruskal-Wallis and χ Results: Between 2022 and 2024, 118 academic hospitals performed 10,394 transcarotid TAVR procedures. Institutions were stratified by 3-year cumulative procedural volume: Q1, 15 to 47 cases (n = 87); Q2, 48 to 77 (n = 87); Q3, 78 to 111 (n = 90); and Q4, 112 to 312 (n = 90). High-volume centers treated older patients (71 years vs 69 years), a higher proportion of white patients (85.4% vs 64.5%), more Medicare beneficiaries (72.4% vs 62.8%), and patients with lower case complexity (Case Mix Index, 2.6 vs 3.5) ( Conclusions: Higher hospital transcarotid TAVR volume is associated with greater resource efficiency, likely attributable in part to lower patient complexity. Mortality and complication outcomes were roughly comparable between transcarotid and transfemoral TAVR, suggesting comparable short-term safety across institutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.